Literature DB >> 9813216

Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV.

H Jin1, D Clarke, H Z Zhou, X Cheng, K Coelingh, M Bryant, S Li.   

Abstract

Infectious human respiratory syncytial virus (RSV) was produced from a cDNA clone that contains 15,222 nucleotides of RSV genome derived from the A2 strain of subgroup A. Recovery of infectious RSV from cDNA required cotransfection of only three expression plasmids encoding the nucleoprotein (N), the phosphoprotein (P), and the major polymerase protein (L). Inclusion of the M2-1 plasmid was not required in the transfection reaction and if included did not significantly increase the rescue efficiency. However, a single nucleotide substitution in the RSV leader region (C to G at position 4 in the antigenomic sense), greatly increased the amount of infectious virus recovered from cDNA. A recombinant RSVA2 virus that expresses an additional structural G protein derived from a subgroup B RSV was also obtained. Both A2 and B strain G glycoproteins were expressed in cells infected with the chimeric RSV. A chimeric RSV that expresses a heterologous subgroup antigen in a live attenuated vaccine candidate may be important for prevention of diseases associated with both RSV subgroup A and subgroup B infection. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813216     DOI: 10.1006/viro.1998.9414

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  Rescue of mumps virus from cDNA.

Authors:  D K Clarke; M S Sidhu; J E Johnson; S A Udem
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 2.  Reverse genetics approach towards understanding pathogenesis of H5N1 Hong Kong influenza A virus infection.

Authors:  M Hatta; G Neumann; Y Kawaoka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

3.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 4.  Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

Authors:  Brian R Murphy; Peter L Collins
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents.

Authors:  H Jin; X Cheng; H Z Zhou; S Li; A Seddiqui
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 6.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 7.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

8.  The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism.

Authors:  Reena Ghildyal; Adeline Ho; Manisha Dias; Lydia Soegiyono; Phillip G Bardin; Kim C Tran; Michael N Teng; David A Jans
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis.

Authors:  Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore
Journal:  Virology       Date:  2012-10-11       Impact factor: 3.616

10.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.